ArticleJournal of clinical tuberculosis and other mycobacterial diseases2026
Hepatic steatosis affects the outcome of anti-tuberculosis treatment in pulmonary tuberculosis patients.
Article in Journal of clinical tuberculosis and other mycobacterial diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pulmonary tuberculosis (PTB) remains a major cause of infectious-disease mortality worldwide. Host metabolic status may shape treatment response, but whether hepatic steatosis affects sputum smear conversion in PTB remains poorly defined. Methods: We performed a retrospective single-center cohort study including newly diagnosed, smear-positive PTB patients treated at Taizhou People's Hospital between January 2022 and December 2025. Patients were classified according to sputum smear conversion status, with delayed conversion defined as persistent smear positivity beyond 8 weeks after initiation of standard anti-tuberculosis therapy. Baseline demographic, clinical, ultrasonographic, laboratory, and cytokine data were collected and compared between groups. Potential factors associated with delayed conversion were evaluated using correlation analysis, multicollinearity assessment, change-in-estimate confounder analysis with the R package chest, and multivariable logistic regression. Results: Clinical screening identified 11 candidate factors. After prioritisation by clinical relevance, correlation structure, collinearity and confounding assessment, six factors were entered into the multivariable model. Hepatic steatosis and IL-18 were positively associated with delayed smear conversion (hepatic steatosis: β = 2.401, OR = 11.036, 95% CI = 2.489-48.934; IL-18: β = 2.396, OR = 10.984, 95% CI = 1.832-65.862). By contrast, T-SPOT positivity was inversely associated with delayed smear conversion (β = -4.199, OR = 0.015, 95% CI = 0.001-0.172). Conclusions: Hepatic steatosis was independently associated with delayed smear conversion in PTB. Baseline cytokine profiles, including IL-6 and IL-18, also differed according to treatment response. These findings suggest that PTB patients with hepatic steatosis may benefit from closer monitoring of treatment response during anti-tuberculosis therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.